Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth.
暂无分享,去创建一个
J. Dodd | C. Crowther | V. Flenady | L. Jones | R. Cincotta
[1] Z. Alfirevic,et al. Cervical stitch (cerclage) for preventing preterm birth in multiple pregnancy. , 2014, The Cochrane database of systematic reviews.
[2] D. Haas,et al. Progestogen for preventing miscarriage. , 2013, The Cochrane database of systematic reviews.
[3] V. Serra,et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial , 2013, BJOG : an international journal of obstetrics and gynaecology.
[4] J. Higgins,et al. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .
[5] K. Nicolaides,et al. Vaginal progesterone vs. cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison metaanalysis. , 2013, American journal of obstetrics and gynecology.
[6] G. Saade,et al. 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. , 2012, American journal of obstetrics and gynecology.
[7] F. Malone,et al. Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. , 2012, American journal of obstetrics and gynecology.
[8] N. Marlow,et al. Trial protocol OPPTIMUM– Does progesterone prophylaxis for the prevention of preterm labour improve outcome? , 2012, BMC Pregnancy and Childbirth.
[9] G. Serour,et al. The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. , 2012, Reproductive biomedicine online.
[10] Ann-Beth Moller,et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications , 2012, The Lancet.
[11] M. Chandiramani,et al. Serum progesterone concentrations in women with a previous preterm birth treated with vaginal progesterone supplementation , 2012, Archives of Disease in Childhood: Fetal and Neonatal Edition.
[12] Alfredo Perales,et al. Progestogens to prevent preterm birth in twin pregnancies: an individual participant data meta-analysis of randomized trials , 2012, BMC Pregnancy and Childbirth.
[13] R. Porcher,et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. , 2012, American journal of obstetrics and gynecology.
[14] K. Nicolaides,et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. , 2012, American journal of obstetrics and gynecology.
[15] W. Grobman. 838: Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm , 2012 .
[16] T. Garite,et al. 194: The impact of maternal weight upon the effectiveness of 17-hydroxyprogesterone in preventing preterm birth among twin gestations , 2012 .
[17] D. Roberts,et al. Cervical stitch (cerclage) for preventing preterm birth in singleton pregnancy. , 2012, The Cochrane database of systematic reviews.
[18] T. Garite,et al. 17-Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double-blind, randomized clinical trial , 2011, BMC Research Notes.
[19] A. Barut,et al. Effect of Progesterone as a Tocolytic and in Maintenance Therapy during Preterm Labor , 2011, Gynecologic and Obstetric Investigation.
[20] P. Bossuyt,et al. Preventing preterm birth with progesterone: costs and effects of screening low risk women with a singleton pregnancy for short cervical length, the Triple P study , 2011, BMC pregnancy and childbirth.
[21] N. Uldbjerg,et al. OC06.01: Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial , 2011 .
[22] N. Uldbjerg,et al. OC01.01: Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone , 2011 .
[23] Taraneh Mohajeri,et al. Efficacy of 17α‐hydroxyprogesterone caproate in prevention of preterm delivery , 2011, The journal of obstetrics and gynaecology research.
[24] S. Brophy,et al. Interventions for latent autoimmune diabetes (LADA) in adults. , 2011, The Cochrane database of systematic reviews.
[25] Ewoud Schuit,et al. 17&agr;-Hydroxyprogesterone Caproate for the Prevention of Adverse Neonatal Outcome in Multiple Pregnancies: A Randomized Controlled Trial , 2011, Obstetrics and gynecology.
[26] K. Nicolaides,et al. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis , 2011, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[27] K. Nicolaides,et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone , 2011, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[28] B. Sibai,et al. Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate. , 2011, American journal of obstetrics and gynecology.
[29] L. Sullivan,et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial , 2011, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[30] M. Harnett,et al. Effect of Prolonged In Vivo Administration of Progesterone in Pregnancy on Myometrial Gene Expression, Peripheral Blood Leukocyte Activation, and Circulating Steroid Hormone Levels , 2011, Reproductive Sciences.
[31] D. Mckenna,et al. A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. , 2011, American journal of perinatology.
[32] T. Garite,et al. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. , 2011, American journal of obstetrics and gynecology.
[33] J. Higgins. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .
[34] نیره خادم غائبی,et al. Efficacy of 17α-Hydroxyprogesterone Caproate in Preterm Delivery Prevention , 2011 .
[35] B. Mol,et al. 98: Mid-pregnancy cervical length as a predictor of preterm birth in multiple pregnancies , 2011 .
[36] T. Garite,et al. 466: 17-hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy , 2011 .
[37] T. Garite,et al. 11: 17-hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity , 2011 .
[38] J. Steichen,et al. 490: Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double-blind, placebo-controlled trial , 2011 .
[39] Everett F Magann,et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. , 2011, American journal of obstetrics and gynecology.
[40] F. Malone,et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-α hydroxyprogesterone caproate , 2010, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[41] A. Ebrashy,et al. OP19.08: Effect of prophylactic progesterone on incidence of preterm labour in spontaneous twin pregnancy, randomized controlled study , 2010 .
[42] T. Garite,et al. Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial. , 2010, American journal of obstetrics and gynecology.
[43] Michele Tarsilla. Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.
[44] J. Norrie,et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): Findings from a trial-based cost-effectiveness analysis , 2010, International Journal of Technology Assessment in Health Care.
[45] F. Malone,et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. , 2010, American Journal of Perinatology.
[46] D. Wing,et al. 17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. , 2009, American journal of obstetrics and gynecology.
[47] Z. Zahiri,et al. MAINTENANCE THERAPY BY VAGINAL PROGESTERONE AFTER THREATENED IDIOPATHIC PRETERM LABOR: A RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL , 2010 .
[48] A. Ramy,et al. Progesterone supplementation for prevention of preterm labor: A randomized controlled trial , 2010 .
[49] M. Sakalli,et al. Progesterone effects on preterm birth in high-risk pregnancies: a randomized placebo-controlled trial , 2011, Archives of Gynecology and Obstetrics.
[50] M. Birjandi,et al. EVALUATION OF THE EFFECT OF PROGESTERONE ON PREVENTION OF PRETERM DELIVERY AND ITS COMPLICATIONS , 2009 .
[51] J. Sonek,et al. 453: A randomized placebo controlled trail of oral micronized progesterone to prevent recurrent preterm birth , 2009 .
[52] Rick W. Martin,et al. 505: Women with prolonged premature rupture of the membranes do not benefit from weekly progesterone: a randomized clinical trial , 2009 .
[53] E. DeFranco,et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial , 2009, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[54] B. Sibai,et al. The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. , 2009, American journal of obstetrics and gynecology.
[55] Rick W. Martin,et al. Progesterone Does Not Prevent Preterm Births in Women with Twins , 2009, Southern medical journal.
[56] A. Novetsky,et al. A randomized trial of cerclage vs. 17 α-hydroxyprogesterone caproate for treatment of short cervix , 2009, Journal of perinatal medicine.
[57] Steven Thornton,et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis , 2009, The Lancet.
[58] Jeffrey S. Robinson,et al. Progesterone after previous preterm birth for prevention of neonatal respiratory distress syndrome (PROGRESS): a randomised controlled trial , 2009, BMC pregnancy and childbirth.
[59] J. Thorp,et al. Prevention of Preterm Birth in Triplets Using 17 Alpha-Hydroxyprogesterone Caproate: A Randomized Controlled Trial , 2009, Obstetrics and gynecology.
[60] Meera Sharma,et al. Intravaginal use of natural micronised progesterone to prevent pre-term birth: A randomised trial in India , 2009, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.
[61] R. Agarwal,et al. Oral micronized progesterone for prevention of preterm birth , 2009, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[62] C. Gyamfi,et al. 689: 17-alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies , 2008 .
[63] E. DeFranco,et al. 467: Natural progesterone administration and the risk of medical complications of pregnancy: Secondary analysis from a multinational, randomized, double blind, placebo-controlled trial , 2008 .
[64] E. DeFranco,et al. 101: Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial , 2008 .
[65] T. Manuck. 38: The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha-hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth , 2008 .
[66] C. Durnwald. 19: The impact of cervical length on risk of preterm birth in twin gestations , 2008 .
[67] B. Sibai,et al. Salivary progesterone and estriol among pregnant women treated with 17-alpha-hydroxyprogesterone caproate or placebo. , 2008, American journal of obstetrics and gynecology.
[68] F. Facchinetti,et al. 17alpha-hydroxy-progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. , 2008, American journal of perinatology.
[69] S. Borna,et al. Progesterone for Maintenance Tocolytic Therapy After Threatened Preterm Labor: A Randomized Controlled Trial , 2008 .
[70] S. Borna,et al. Progesterone for maintenance tocolytic therapy after threatened preterm labour: A randomised controlled trial , 2008, The Australian & New Zealand journal of obstetrics & gynaecology.
[71] E. DeFranco,et al. 15: Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: Secondary analysis from a randomized, double-blind, placebo-controlled trial , 2007 .
[72] E. DeFranco,et al. 702: Is there a racial disparity in the efficacy of progesterone to prevent preterm birth? , 2007 .
[73] J. Weeks,et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double‐blind, placebo‐controlled trial , 2007, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[74] E. Thom,et al. Follow-up of Children Exposed In Utero to 17 &agr;-Hydroxyprogesterone Caproate Compared With Placebo , 2007, Obstetrics and gynecology.
[75] J. Weeks,et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial , 2007, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[76] Elizabeth A Thom,et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. , 2007, The New England journal of medicine.
[77] K. Nicolaides,et al. Progesterone and the risk of preterm birth among women with a short cervix. , 2007, The New England journal of medicine.
[78] Mike Clarke,et al. A systematic review and quality assessment of systematic reviews of fetal fibronectin and transvaginal length for predicting preterm birth. , 2007, European journal of obstetrics, gynecology, and reproductive biology.
[79] H. Scheepers,et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial , 2007, BMC pregnancy and childbirth.
[80] F. Facchinetti,et al. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. , 2007, American journal of obstetrics and gynecology.
[81] Michael F. Wangler,et al. Racial disparity in the frequency of recurrence of preterm birth. , 2007, American journal of obstetrics and gynecology.
[82] Brenner,et al. Membranes From Rhesus Macaques: Evidence for Functional Progesterone Withdrawal at Parturition , 2007 .
[83] F. Facchinetti,et al. 17 Alpha hydroxy-progesterone caproate (17P) treatment reduces cervical shortening inhibiting cervical interleukin-1 secretion , 2006 .
[84] R. Larkin,et al. A randomized trial of cerclage versus 17-hydroxyprogesterone (17p) for the treatment of short cervix , 2006 .
[85] M. Klebanoff. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol , 2006 .
[86] A. Northen. 4-Year follow-up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero , 2006 .
[87] D. Rouse,et al. A randomized controlled trial of 17-hydroxyprogesterone caproate (17-OHPC) for the prevention of preterm birth in twins , 2006 .
[88] J. Dodd,et al. Prenatal administration of progesterone for preventing preterm birth. , 2006, The Cochrane database of systematic reviews.
[89] Gretchen Koontz. Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17-OHCP) in preventing recurrent preterm delivery? , 2005 .
[90] L. Hefler,et al. Oral dydrogesterone treatment during the first trimester of pregnancy: The prevention of miscarriage study (PROMIS). A double-blind, prospectively randomized, placebo-controlled, parallel group trial , 2005, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[91] B. Sibai,et al. Does Progesterone Treatment Influence Risk Factors for Recurrent Preterm Delivery? , 2005, Obstetrics and gynecology.
[92] B. Sibai,et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high-risk for preterm delivery. , 2005, American journal of obstetrics and gynecology.
[93] Philip Steer,et al. The epidemiology of preterm labour , 2005, BJOG : an international journal of obstetrics and gynaecology.
[94] W. Callaghan,et al. Estimated Effect of 17 Alpha-Hydroxyprogesterone Caproate on Preterm Birth in the United States , 2005, Obstetrics and gynecology.
[95] B. Sibai,et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. , 2004, American journal of obstetrics and gynecology.
[96] E. Sullivan,et al. Australia's mothers and babies 2007 , 2008 .
[97] B. Sibai. Plasma CRH levels at 16-20 weeks do not predict preterm delivery in women at high-risk for preterm delivery , 2004 .
[98] J. Dodd,et al. Antenatal administration of progesterone for preventing spontaneous preterm birth , 2004 .
[99] William McGuire,et al. Epidemiology of preterm birth , 2004, BMJ : British Medical Journal.
[100] S. Gates,et al. How should randomised trials including multiple pregnancies be analysed? , 2004, BJOG : an international journal of obstetrics and gynaecology.
[101] H. Faller. [Intention-to-treat]. , 2004, Die Rehabilitation.
[102] J. Martin,et al. Births: final data for 2002. , 2003, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[103] P. Meis. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha-hydroxyprogesterone (17P) , 2003 .
[104] Acog. ACOG Committee on Obstetric Practice Number 291, November 2003: Use of Progesterone to Reduce Preterm Birth , 2003 .
[105] J. Kleijnen,et al. Accuracy of cervical transvaginal sonography in predicting preterm birth: a systematic review , 2003 .
[106] C. Mendelson,et al. A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize progesterone receptor function and contribute to the initiation of parturition , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[107] M. Greene. Progesterone and preterm delivery--deja vu all over again. , 2003, The New England journal of medicine.
[108] Steve N Caritis,et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. , 2003, The New England journal of medicine.
[109] S. Thornton,et al. The involvement of progesterone in the onset of human labour. , 2003, European journal of obstetrics, gynecology, and reproductive biology.
[110] A. L. Bernal,et al. Mechanisms of labour—biochemical aspects , 2003 .
[111] J. Lumley. Defining the problem: the epidemiology of preterm birth , 2003, BJOG : an international journal of obstetrics and gynaecology.
[112] J. Iams. Supplemental progesterone to prevent preterm birth. , 2003, American journal of obstetrics and gynecology.
[113] M. Zugaib,et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. , 2003, American journal of obstetrics and gynecology.
[114] D. Haas,et al. Progestogen for preventing miscarriage. , 2003, The Cochrane database of systematic reviews.
[115] A. López Bernal. Mechanisms of labour--biochemical aspects. , 2003, BJOG : an international journal of obstetrics and gynaecology.
[116] Lucas M Bachmann,et al. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review , 2002, BMJ : British Medical Journal.
[117] C. Crowther,et al. Who remains undelivered more than seven days after a single course of prenatal corticosteroids and gives birth at less than 34 weeks? , 2002, The Australian & New Zealand journal of obstetrics & gynaecology.
[118] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[119] S. Thompson,et al. How should meta‐regression analyses be undertaken and interpreted? , 2002, Statistics in medicine.
[120] R. Brenner,et al. Progesterone receptor Localization and Isoforms in Myometrium, Decidua, and Fetal Membranes From Rhesus Macaques: Evidence for Function Progresterone Withdrawal at Parturtion , 2002, The Journal of the Society for Gynecologic Investigation: JSGI.
[121] R. Resnik. Intrauterine growth restriction. , 2002, Obstetrics and gynecology.
[122] F. Corrado,et al. A randomised trial of progesterone prophylaxis after midtrimester amniocentesis. , 2002, European journal of obstetrics, gynecology, and reproductive biology.
[123] P. Bennett,et al. Interactions between progesterone receptor isoforms in myometrial cells in human labour. , 2001, Molecular human reproduction.
[124] K. Leveno,et al. Recurrence of Preterm Birth in Singleton and Twin Pregnancies , 2001, Obstetrics and gynecology.
[125] E. Norwitz,et al. The epidemiology of preterm labor. , 2001, Seminars in perinatology.
[126] D. Mattison,et al. Preterm delivery: a public health perspective. , 2001, Paediatric and perinatal epidemiology.
[127] M. Kramer,et al. The contribution of mild and moderate preterm birth to infant mortality. Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System. , 2000, JAMA.
[128] H. Wilson,et al. Rates of and factors associated with recurrence of preterm delivery. , 2000, JAMA.
[129] M. Dombrowski,et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. , 1999, American journal of obstetrics and gynecology.
[130] R. Hagan,et al. Hospital admissions in the first year of life in very preterm infants , 1999, Journal of paediatrics and child health.
[131] M. Hack. Consideration of the use of health status, functional outcome, and quality-of-life to monitor neonatal intensive care practice. , 1999, Pediatrics.
[132] D. Rouse,et al. Prevention of premature birth. , 1998, The New England journal of medicine.
[133] Hans H. Zingg,et al. Inhibition of oxytocin receptor function by direct binding of progesterone , 1998, Nature.
[134] M. Hannah,et al. Fetal Fibronectin as a Predictor of Preterm Birth: An Overview , 1998, American journal of perinatology.
[135] M. Novy,et al. Inhibition and augmentation of progesterone production during pregnancy: effects on parturition in rhesus monkeys. , 1997, American journal of obstetrics and gynecology.
[136] E. Albrecht,et al. Actions of placental and fetal adrenal steroid hormones in primate pregnancy. , 1995, Endocrine reviews.
[137] C. Hobel,et al. The West Los Angeles Preterm Birth Prevention Project. I. Program impact on high-risk women. , 1994, American journal of obstetrics and gynecology.
[138] G. Berkowitz,et al. Epidemiology of preterm birth. , 1993, Epidemiologic reviews.
[139] F. Stanley. Survival and cerebral palsy in low birthweight infants: implications for perinatal care. , 1992, Paediatric and perinatal epidemiology.
[140] P. Lamy. Adverse drug effects. , 1990, Clinics in geriatric medicine.
[141] J. Newnham,et al. A review of the obstetric and medical complications leading to the delivery of infants of very low birthweight , 1988 .
[142] A. Stark,et al. Respiratory distress syndrome. , 1986, Pediatric clinics of North America.
[143] R. Carr-Hill,et al. The repetition of spontaneous preterm labour. , 1986, British journal of obstetrics and gynaecology.
[144] M. Lancet,et al. Prevention of premature labor by 17α-hydroxyprogesterone caproate , 1985 .
[145] B. Block,et al. Preterm delivery is not predicted by serial plasma estradiol or progesterone concentration measurements. , 1984, American journal of obstetrics and gynecology.
[146] G. Essed,et al. Predictive value of uterine contractility and the serum levels of progesterone and oestrogens with regard to preterm labour. , 1984, Gynecologic and obstetric investigation.
[147] F. Kubli. Mode of delivery , 1983 .
[148] L. Gilstrap,et al. The effect of 17α-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population , 1983 .
[149] R. Tuimala,et al. Inefficacy of 17α‐Hydroxyprogesterone Caproate in the Prevention of Prematurity in Twin Pregnancy , 1980, Obstetrics and gynecology.
[150] H. Hoffman,et al. The tendency to repeat gestational age and birth weight in successive births. , 1979, American journal of obstetrics and gynecology.
[151] C. Rumeau-rouquette,et al. A Comparative Study of the Efficiency of Hydroxyprogesterone Caproate and of Chlormadinone Acetate in the Prevention of Premature Labor , 1979, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[152] T. M. King,et al. Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. , 1975, The New England journal of medicine.
[153] M. Kaminski,et al. Multifactorial study of the risk of prematurity at 32 weeks of gestation. I. A study of the frequency of 30 predictive characteristics , 1974, Journal of perinatal medicine.
[154] M. Kaminski,et al. Prediction of low birthweight and prematurity by a multiple regression analysis with maternal characteristics known since the beginning of the pregnancy. , 1973, International journal of epidemiology.
[155] K Funaki,et al. [Prevention of premature birth]. , 1971, Sanfujinka no jissai. Practice of gynecology and obstetrics.
[156] G. Feldman,et al. Prolonged gynecologic and endocrine manifestations subsequent to administration of medroxyprogesterone acetate during pregnancy. , 1966, American journal of obstetrics and gynecology.
[157] W. Brenner,et al. Effect of medroxyprogesterone acetate upon the duration and characteristics of human gestation and labor. , 1962, American journal of obstetrics and gynecology.